Open AccessS111: REPEATED INFUSIONS OF ESCALATING DOSES OF EXPANDED AND ACTIVATED AUTOLOGOUS NATURAL KILLER CELLS IN MINIMAL RESIDUAL DISEASE‐POSITIVE PH+ ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. A GIMEMA PHASE 1 TRIAL
Author(s) -
Torelli G. F.,
Chiaretti S.,
Peragine N.,
Barberi W.,
Santodonato L.,
D'Agostino G.,
Abruzzese E.,
Del Principe M. I.,
Mancino A.,
Matarazzo M.,
Bafti M. S.,
Mancini M,
Messina M.,
Castiello L.,
Guarini A.,
Foà R.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843340.37667.57
Subject(s) - medicine , minimal residual disease , blinatumomab , tolerability , immunotherapy , clinical endpoint , oncology , immunology , clinical trial , gastroenterology , leukemia , adverse effect , lymphoblastic leukemia , cancer